Rafarma Pharmaceuticals, a Russia-based manufacturing facility that produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products, today said it has commenced production of the antibiotic Ceftriaxone.
Ceftriaxone is for the treatment of inflammatory infections of the organs of the abdominal cavity, such as peritonitis, as well as inflammatory diseases of the gastrointestinal and bile-excreting tracts.
Rafarma points to 2011 official statistics that estimate the Ceftriaxone market in Russia at more than USD$51 million each year. As a participant in the Russian Federal Program for “Domestic-Produced Vital Drugs,” Rafarma said it plans to take as much as 50 percent of the Russian market for Ceftriaxone.
Rafarmaalso said it stands to benefit from a recent long-term distribution agreement between ZAO “SIA International” and the Russian national retail chain OAO “A5 Pharmacy Ltd.,” which provides Rafarma with a national presence in the Russian Federation retail pharmaceutical market.
“The agreements with these drug store chains and pharmaceutical supply companies moves Rafarma in a very positive direction and also shows the respect these companies have for Rafarma. I am extremely pleased that we get to work with such qualified partners that have the confidence in Rafarmato lock in long-term contracts,” Rafarma CEO David Anderson stated in the press release.
“Rafarma’s increase in production and penetration of market share becomes even more assured with the 17 national distributors we have signed to long-term agreements,” he continued. “These contracts were an integral part of Rafarma’s expansion plan and will play a vital role in the expansion of operations. Rafarma has positioned itself to become one of the five leading pharmaceutical companies in the Russian Federation.”
For more information visit www.rafarma.com
Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board